-
Momenta Pharmaceuticals Announces Completion of Proposed Sale to Johnson & Johnson
01 Oct 2020 12:44 GMT
CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, …
-
Lifshitz Law Firm, P.C. Announces Investigation of Cancer Genetics, Inc., Momenta Pharmaceuticals, Inc., Principia Biopharma Inc., and Yintech Investment Holdings Limited
01 Sep 2020 23:17 GMT
… -mail at info@jlclasslaw.com.
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)
Lifshitz Law … at info@jlclasslaw.com.
ATTORNEY ADVERTISING.© 2020 Lifshitz Law Firm, P …
-
SHAREHOLDER ALERT: WeissLaw LLP Investigates Momenta Pharmaceuticals, Inc.
20 Aug 2020 02:17 GMT
… 47;www.weisslawllp.com/momenta-pharmaceuticals-inc/
Or please … information), consumer fraud (including false advertising, defective products, or other … shareholder-alert-weisslaw-llp-investigates-momenta-pharmaceuticals-inc-301115235.html
SOURCE …
-
(MNTA) Alert: Johnson Fistel Investigates Proposed Sale of Momenta Pharmaceuticals; Are Shareholders Getting a Fair Price?
19 Aug 2020 15:32 GMT
… whether the board members of Momenta Pharmaceuticals, Inc. ("Momenta" or … ;/www.johnsonfistel.com. Attorney advertising. Past results do not guarantee … -fistel-investigates-proposed-sale-of-momenta-pharmaceuticals-are-shareholders-getting-a-fair …
-
MOMENTA PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
19 Aug 2020 16:59 GMT
… . announces that it is investigating Momenta Pharmaceuticals, Inc. (“Momenta”) (NASDAQ GS: … ;www.rigrodskylong.com/cases-momenta-pharmaceuticals-inc. If you would … corporate class actions nationwide. Attorney advertising. Prior results do not …
-
Momenta Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Nipocalimab in HDFN
28 Jul 2020 11:15 GMT
CAMBRIDGE, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced that its novel drug candidate, nipocalimab, has received rare pediatric disease designation from the U.S. Food and Drug Administration (FDA) …
-
Momenta Pharmaceuticals Announces Positive Topline Data from Interim Analysis of Phase 2 Vivacity-MG Study of Nipocalimab (M281) in Generalized Myasthenia Gravis (gMG)
15 Jun 2020 11:05 GMT
- Trial met primary endpoint with a strong relationship between Immunoglobulin G (IgG) reduction and MG-ADL clinical benefit (p<0.0001) -
- Nipocalimab induced a rapid and durable response in the myasthenia gravis activities of daily living score …
-
Momenta Pharmaceuticals Announces Pricing of Public Offering of Common Stock
12 Dec 2019 13:00 GMT
CAMBRIDGE, Mass., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced the pricing of its underwritten public offering of 14,516,130 shares of its common stock at the public offering price of $15.50 per share for …
-
Momenta Pharmaceuticals Announces Poster Presentation at the 61st American Society of Hematology Annual Meeting and Exposition
07 Nov 2019 13:00 GMT
CAMBRIDGE, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced that Santiago Arroyo, M.D., Ph.D., Chief Medical Officer, will deliver a poster presentation at the upcoming 61st American Society of …
-
Lifshitz & Miller LLP Announces Investigation of Aratana Therapeutics, Inc., FXCM Inc., Innocoll Holdings plc, Momenta Pharmaceuticals, Inc., Omnicom Group Inc., Perrigo Company plc, Santander Consumer USA Holdings Inc. and The Interpublic Group of…
25 Mar 2017 00:17 GMT
… mail at info@jlclasslaw.com.
Momenta Pharmaceuticals, Inc. (MNTA)
Lifshitz … price-fixing in video-advertising production.
If you are … scheme with other video-advertising producers.
If you are … at info@jlclasslaw.com.
ATTORNEY ADVERTISING. © 2017 Lifshitz & …
About
© 1995-2025